10634177

=> d his

(FILE 'HOME' ENTERED AT 14:43:20 ON 01 JUL 2004)

FILE 'REGISTRY' ENTERED AT 14:46:18 ON 01 JUL 2004
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 2 S L2
L4 906 S L2 SSS FULL
L5 STRUCTURE UPLOADED
L6 8 S L5 SUB=L4 SAMPLE
L7 227 S L5 SSS FULL SUB=L4
L8 STRUCTURE UPLOADED
L9 0 S L8 SUB=L4 SAMPLE
L10 10 S L8 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 14:53:51 ON 01 JUL 2004
L11 42 S L7
L12 5 S L10
L13 46 S L11 OR L12
L14 38 S L13 NOT AMINO
L15 33 S L14 NOT ESTER
L16 32 S L15 NOT BUTANONE
L17 18 S L16 NOT CYAN?

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1

G2 C,N

G3 C,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1

G2 C,N,Cy

G3 C,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l5
L5 HAS NO ANSWERS
L5 STR

10634177



G1

G2 C,N,Cy

G3 C,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1

G2 C,N,Cy

G3 C,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d 1-18 bib abs hitstr

L17 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:143150 CAPLUS
DN 140:175193
TI Heterobicyclic metalloproteinase inhibitors, pharmaceutical compositions, and therapeutic use
IN Wilson, Michael William
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014908	A1	20040219	WO 2003-IB3478	20030804
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004039012	A1	20040226	US 2003-634177	20030805
PRAI	US 2002-403098P	P	20020813		

OS MARPAT 140:175193
GI

10634177



I

AB The invention discloses fused bicyclic metalloproteinase inhibitors I [A = C2-6 alkynyl, bond, etc.; X, Y = O, S, etc. (with proviso); dashed lines = optional double bonds; B = substituted pyridinyl; R1 = C1-6 alkyl, C2-6 alkenyl, etc.], as well as pharmaceutical compns. and methods of treating arthritis, inflammation, cancer, and other disorders.

IT **658037-50-4 658037-51-5 658037-52-6**
658037-59-3 658037-60-6 658037-61-7
658037-66-2 658037-67-3 658037-68-4
658037-75-3 658037-76-4 658037-77-5
658037-84-4 658037-85-5 658037-86-6
658037-92-4 658037-93-5 658037-94-6
658038-03-0 658038-05-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterobicyclic metalloproteinase inhibitors, pharmaceutical compns., and therapeutic use)

RN 658037-50-4 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 658037-51-5 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-52-6 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-59-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-60-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-61-7 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 658037-66-2 CAPLUS
CN 7H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-8-methyl-7-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-67-3 CAPLUS
CN 7H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-8-methyl-7-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-68-4 CAPLUS
CN 7H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-8-methyl-7-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-75-3 CAPLUS
CN 7H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-7-oxo- (9CI) (CA INDEX NAME)



RN 658037-76-4 CAPLUS
CN 7H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-8-methyl-7-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-77-5 CAPLUS
CN 7H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-8-methyl-7-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-84-4 CAPLUS
CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-8-methyl-5-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-85-5 CAPLUS
CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-8-methyl-5-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-86-6 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5-oxo-2-[[(phenylmethyl)amino]carbonyl]-5H-1,3,4-thiadiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 658037-92-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-8-methyl-5-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-93-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-8-methyl-5-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-94-6 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5-oxo-2-[[(phenylmethyl)amino]carbonyl]-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 658038-03-0 CAPLUS
CN 5H-[1,2,4]Thiadiazolo[2,3-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658038-05-2 CAPLUS
CN 5H-Isothiazolo[2,3-a]pyridine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-4-methyl-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:342561 CAPLUS
DN 139:214379
TI Oxidative cyclization of N-methyl- and N-benzoylpyridylthioureas. Preparation of new thiazolo[4,5-b]- and -[5,4-b]pyridine derivatives
AU Jouve, Karine; Bergman, Jan
CS Unit for Organic Chemistry, Department of Biosciences, Karolinska Institute and Sodertorn University College, Huddinge, SE-14157, Swed.
SO Journal of Heterocyclic Chemistry (2003), 40(2), 261-268
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
OS CASREACT 139:214379
AB Cyclization of N-methyl- and N-benzoylpyridylthioureas, prepared from the corresponding aminopyridines, has been realized using various conditions. With bromine in acetic acid or potassium ferricyanide, the cyclization occurred on the nitrogen of the pyridine ring and pyridinium salts or 1,2,4-thiadiazolo[2,3-a]pyridylidene systems were obtained. On the other hand, treatment of the thioureas with sodium methoxide in N-methylpyrrolidinone (NMP) led to formation of thiazolo[4,5-b]- and -[5,4-b]pyridines, which are interesting targets for biol. evaluation.
IT **588730-04-5P 588730-05-6P 588730-06-7P**
588730-07-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of thiazolopyridine derivs. by oxidative cyclization of N-methyl- and N-benzoylpyridylthioureas)
RN 588730-04-5 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 6-bromo-2-(methylamino)-, bromide (9CI) (CA INDEX NAME)



RN 588730-05-6 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(methylamino)-6-phenyl-, bromide (9CI) (CA INDEX NAME)



RN 588730-06-7 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(benzoylamino)-6-bromo-, inner salt (9CI) (CA INDEX NAME)



RN 588730-07-8 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(benzoylamino)-6-phenyl-, inner salt (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:215690 CAPLUS
DN 139:101004
TI A concise and stereoselective synthesis of (+/-)-erythro-methylphenidate
AU Russowsky, Dennis; Amaro da Silveira Neto, Brenno
CS Instituto de Quimica, Universidade Federal do Rio Grande do Sul, Porto Alegre, 91501-970, Brazil
SO Tetrahedron Letters (2003), 44(14), 2923-2926
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 139:101004
GI



AB A concise and stereoselective synthesis of racemic erythro-methylphenidate (I) is described. The coupling reaction between piperidine-2-thione and Me 2-bromo-2-phenylacetate afforded β-enaminocarbonyl compound II in 60% yield by a modified Eschenmoser sulfide contraction reaction. In most cases bicyclic thiazolidinone III was also produced. Diastereoselective reduction of II in the presence of borohydrides furnished (+/-)-erythro-methylphenidate (I) in good yields with dr >95%.

IT **560132-19-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phenylpyridothiazolidinone via substitution of bromo(phenyl)acetate with piperidinethione followed by heterocyclization)

RN 560132-19-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-3(2H)-one, 6,7-dihydro-2-phenyl- (9CI) (CA INDEX NAME)

10634177



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:139712 CAPLUS
DN 134:259378
TI Application of simulated annealing approach for structure solution of molecular crystals from x-ray laboratory powder data
AU Zhukov, S. G.; Chernyshev, V. V.; Babaev, E. V.; Sonneveld, E. J.; Schenk, H.
CS Department of Chemistry, Moscow State University, Moscow, 119899, Russia
SO Zeitschrift fuer Kristallographie (2001), 216(1), 5-9
CODEN: ZEKRDZ; ISSN: 0044-2968
PB R. Oldenbourg Verlag
DT Journal
LA English
AB The simulated annealing approach was successfully applied to solve three unknown mol. structures from x-ray laboratory powder data using a priory known structural fragments. The structures of 2-chloro-1-(p-nitrophenacyl)pyridinium bromide (orthorhombic, space group Fdd2), 2-(p-nitrophenyl)thiazolo[3,2-a]pyridinium perchlorate (orthorhombic, space group Pbca), and 3-(p-nitrobenzoyl)-2-oxooxazolo[3,2-a]pyridine (monoclinic, space group P21/n) were determined Some possible developments of the method are discussed.
IT **213765-84-5**, 2-(p-Nitrophenyl)thiazolo[3,2-a]pyridinium perchlorate
RL: PRP (Properties)
(crystal structure from x-ray powder data by simulated annealing approach)
RN 213765-84-5 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(4-nitrophenyl)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 213765-83-4
CMF C13 H9 N2 O2 S



CM 2

CRN 14797-73-0
CMF Cl O4



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:530717 CAPLUS
DN 133:266804

10634177

TI New routes to polyfunctionally substituted benzene, pyridazines and thiophene derivatives
AU Erian, Ayman Wahba; Abdel, Abu Zeid; Hassanien, Baset; Mohamed, Nadia Ragab
CS Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt
SO Phosphorus, Sulfur and Silicon and the Related Elements (1999), 155, 147-155
CODEN: PSSLEC; ISSN: 1042-6507
PB Gordon & Breach Science Publishers
DT Journal
LA English
OS CASREACT 133:266804
GI



I

AB Di-Et 2-phenyl-3-thiocyanopropene-1,1-dicarboxylate (I) as a key precursor in heterocyclic synthesis. The applicability and synthetic potency of I are studied to afford substituted benzene, pyridazines and thiophene derivs.
IT **298184-08-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted benzene, pyridazines and thiophene derivs. from phenylthiocyanopropenedicarboxylate via cyclocondensation reactions)
RN 298184-08-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-6-carboxylic acid, 2-cyano-5-oxo-3,7-diphenyl-8-thiocyanato-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:719574 CAPLUS
DN 132:78498
TI Halocyclization of 2-allylthiopyridine
AU Kim, D. G.
CS Chelyabinsk State University, Chelyabinsk, 454021, Russia
SO Chemistry of Heterocyclic Compounds (New York)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (1999), 35(3), 290-292
CODEN: CHCCAL; ISSN: 0009-3122
PB Consultants Bureau
DT Journal
LA English
OS CASREACT 132:78498
AB 2-Allylthiopyridine reacts with iodine to form 3-iodomethyl-2,3-dihydrothiazolo[3,2-a]pyridinium triiodide, but in reaction with bromine a mixture of 3- and 2-bromomethyl-2,3-dihydrothiazolo[3,2-a]pyridinium bromides is obtained.
IT **253670-38-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(halocyclization of (allylthio)pyridine)
RN 253670-38-1 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(bromomethyl)-2,3-dihydro-, bromide (9CI) (CA INDEX NAME)



● Br^-

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:673580 CAPLUS
DN 132:35643
TI Novel route to b-fused thiazoles starting from a 2-chloro-1-phenacylpyridinium salt and KSCN. Crystal structures of thiazolo- and oxazolo[3,2-a]pyridinium thiocyanates
AU Babaev, Eugene V.; Bush, Alexander A.; Orlova, Irina A.; Rybakov, Viktor B.; Zhukov, Sergey G.
CS Chemistry Department, Moscow State University, Moscow, 119899, Russia
SO Tetrahedron Letters (1999), 40(42), 7553-7556
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
AB Reaction of 2-chloro-1-phenacylpyridinium bromide with KSCN led to 2-aminothiazolo[3,2-a]pyridinium salts, thus opening a novel route to fused thiazoles. In reaction with KSCN, oxazolo[3,2-a]pyridinium perchlorate was converted to the thiocyanate.
IT **252663-89-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminothiazolo[3,2-a]pyridinium salts and oxazolo[3,2-a]pyridinium thiocyanate)
RN 252663-89-1 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-amino-3-(4-nitrobenzoyl)-, thiocyanate (9CI) (CA INDEX NAME)

CM 1

CRN 252663-88-0
CMF C14 H10 N3 O3 S



CM 2

CRN 302-04-5
CMF C N S

$^-S-C\equiv N$

IT **252663-90-4P 252664-08-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminothiazolo[3,2-a]pyridinium salts and oxazolo[3,2-a]pyridinium thiocyanate)
RN 252663-90-4 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-amino-3-(4-nitrobenzoyl)-, perchlorate (9CI) (CA INDEX NAME)

10634177

CM 1

CRN 252663-88-0
CMF C14 H10 N3 O3 S



CM 2

CRN 14797-73-0
CMF Cl O4



RN 252664-08-7 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-amino-3-(4-nitrobenzoyl)-, thiocyanate, hydrate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 7732-18-5
CMF H2 O

H_2O

CM 2

CRN 252663-89-1
CMF C14 H10 N3 O3 S . C N S

CM 3

CRN 252663-88-0
CMF C14 H10 N3 O3 S



CM 4

CRN 302-04-5
CMF C N S



10634177

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:661861 CAPLUS
DN 132:35655
TI Intramolecular oxidative cyclizations in heteroarylthioureas: a versatile pathway to bridgehead heterocyclic systems
AU Castro, Ana; Martinez, Ana
CS Instituto de Quimica Medica (CSIC), Madrid, 28006, Spain
SO Journal of Heterocyclic Chemistry (1999), 36(4), 991-995
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
AB Intramol. oxidns. of N-alkyl-N'-heteroarylthioureas represent a facile and versatile synthetic pathway to fused heterocyclic systems including bridgehead ones. These kinds of heterocycles are the main feature in common biol. active compds.
IT **252270-12-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(intramol. oxidative cyclization in heteroarylthioureas as versatile pathway to bridgehead heterocyclic systems)
RN 252270-12-5 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(dimethylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:594917 CAPLUS
DN 131:214299
TI Preparation of arylalkylamine or heteroarylalkylamine derivatives as local anesthetic agents
IN Okada, Shigeya; Ishihama, Yutaka; Ichioka, Takahiro; Matsui, Takeaki; Yamazaki, Hirofumi; Hijikuro, Kohshi; Naruse, Tomohiro; Hoshino, Takashi
PA Maruho Kabushikikaisha, Japan
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9945914	A1	19990916	WO 1999-JP1136	19990308
W: CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI JP 1998-63550		19980313		

OS MARPAT 131:214299
AB Disclosed is a local anesthetic agent comprising, as an active constituent, an alkyl amine derivative having general formula ACR5R6 CR1R2(CH2)nNR3R4 (wherein A is a substituted or unsubstituted aryl or heteroaryl group; R1 and R2 may be the same or different and are a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy, a lower alkylthio, an aryl, a lower alkenyl, or an aralkyl; R3 and R4 may be the same or different, and are a hydrogen atom, a lower alkyl group, a lower alkenyl, a cycloalkyl, or form, together with a nitrogen atom to which they are bonded, a 5 to 7-membered, substituted or unsubstituted heterocyclic ring; with respect to R5 and R6, one is a hydrogen atom and the other is a lower alkoxyl group, or they together form an oxo group or a lower alkylenedioxy group optionally substituted

with a lower alkyl group; and n is 1 or 2). These compds. are useful as surface, infiltration, or conduction (nerve blocking) anesthesia. Thus, a mixture of 1-(4-ethylphenyl)-2-methylpropan-1-one, imidazole, and MeOH was refluxed for 4 h to give 1-(4-ethylphenyl)-3-(1H-imidazol-1-yl)-2-methylpropan-1-one (I). In a surface anesthesia model testing reflex of rabbit cornea in vivo, I and 1-[5-(4-chlorophenyl)furan-2-yl]-2-methyl-3-(pyrrolidin-1-yl)propane-1-one maleate in vivo showed ED50 of 0.343 and 0.031 (concentration unit unspecified), resp., vs. 1.411 for lidocaine hydrochloride.

IT **243450-22-8P 243450-24-0P 243450-84-2P**
243450-87-5P 243450-90-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylalkylamine or heteroarylalkylamine derivs. as local anesthetic agents)

RN 243450-22-8 CAPLUS
CN 1-Propanone, 2-methyl-3-(1-pyrrolidinyl)-1-(5H-thiazolo[3,2-a]pyridin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 243450-24-0 CAPLUS
CN 1-Propanone, 2-methyl-3-(1-pyrrolidinyl)-1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 243450-84-2 CAPLUS
CN 1-Propanone, 3-(1H-imidazol-1-yl)-2-methyl-1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 243450-87-5 CAPLUS
CN 1-Butanone, 2-(1H-imidazol-1-ylmethyl)-1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 243450-90-0 CAPLUS
CN 1-Butanone, 2-(1H-imidazol-1-ylmethyl)-3-methyl-1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



IT **243451-95-8 243452-33-7 243452-37-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylalkylamine or heteroarylalkylamine derivs. as local anesthetic agents)
RN 243451-95-8 CAPLUS
CN 1-Propanone, 1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 243452-33-7 CAPLUS
CN 1-Butanone, 1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 243452-37-1 CAPLUS
CN 1-Butanone, 3-methyl-1-(5H-thiazolo[3,2-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:256044 CAPLUS
DN 126:343516
TI New and convenient syntheses of anhydro-2-alkyl-3-iminothiazolo[3,2-a]pyridinium hydroxide derivatives
AU Barton, Derek H. R.; Liu, Wansheng
CS Department of Chemistry, Texas AandM University, College Station, TX, 77843, USA
SO Tetrahedron Letters (1997), 38(14), 2435-2438
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 126:343516
AB The 2-alkyl derivs. of anhydro-3-trifluoroacetyliminothiazolo[3,2-a]pyridinium hydroxide were synthesized in quant. yield by treatment of either 2-(pyridin-2-thiyl)carboxamides or the corresponding nitriles with trifluoroacetic anhydride in dichloromethane.
IT **189809-84-5P 189809-85-6P 189809-86-7P**
189809-87-8P 189809-88-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of anhydroiminothiazolo[3,2-a]pyridinium hydroxide derivs.)

RN 189809-84-5 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(cyclohexylmethyl)-3-[(trifluoroacetyl)amino]-, inner salt (9CI) (CA INDEX NAME)



RN 189809-85-6 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(2-methylpropyl)-3-[(trifluoroacetyl)amino]-, inner salt (9CI) (CA INDEX NAME)



RN 189809-86-7 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(3-phenylpropyl)-3-[(trifluoroacetyl)amino]-, inner salt (9CI) (CA INDEX NAME)



RN 189809-87-8 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(2,2-dimethylpropyl)-3-[(trifluoroacetyl)amino]-, inner salt (9CI) (CA INDEX NAME)



RN 189809-88-9 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-3-[(trifluoroacetyl)amino]-, inner salt (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:169800 CAPLUS

10634177

DN 126:264050
TI Base promoted transformation on thiadiazolopyridinium chlorides
AU Martinez, Ana; Castro, Ana; Fayet, J. P.
CS Instituto de Quimica Medica, CSIC, Madrid, 28006, Spain
SO Journal of Heterocyclic Chemistry (1997), 34(1), 337-340
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
AB 1,2,4-Thiadiazolo[2,3-a]pyridinium chlorides undergo a very facile base promoted transformation to give bispyridylimino-1,2,4-thiadiazolidines. The unequivocal structural assignment of these last compds. was achieved by spectroscopic 1H, 13C and 15N two dimensional methods.
IT **188830-69-5 188830-70-8 188830-71-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(conversion of thiadiazolopyridinium chlorides to bis(pyridylimino)thiadiazolidines)
RN 188830-69-5 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(methylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 188830-70-8 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(ethylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 188830-71-9 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-[(phenylmethyl)amino]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:116871 CAPLUS
DN 126:171500
TI Ketene gem-dithiols; a convenient one-step procedure from aliphatic active methylenes: reactions and synthesis of polyfunctionally substituted thia-

and azaheteroaromatics
AU Zayed, Salem E.
CS Dep. Chem., South Valley Univ., Kena, 83511, Egypt
SO Phosphorus, Sulfur and Silicon and the Related Elements (1996), 116, 29-37
CODEN: PSSLEC; ISSN: 1042-6507
PB Gordon & Breach
DT Journal
LA English
AB It has been reported in the current literature that the isolation of certain ketene gem dithiols has failed due to dimerization. Generation of ketene gem-dithiols via trapping with other reactants led to formation of pyridine, pyrrole, pyridothiadiazole and pyrazolone derivs.
IT **187280-41-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 187280-41-7 CAPLUS
CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-8-carboxylic acid, 2-(4-chlorophenyl)-6-cyano-7-methyl-5-oxo- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:81468 CAPLUS
DN 126:199519
TI Iminium carbonic acid derivative salts. X. Synthesis of N,S-containing heterobicycles from N-protected 2-methylthio-1,3-thiazinium and 2-methylthiothiazolium salts. Part 2. Reaction of N-protected 2-methylthio-1,3-thiazinium and 2-methylthiothiazolium salts with vinylogous CH-acidic compounds
AU Hanefeld, Wolfgang; Naeeni, Mahmoud; Schlitzer, Martin
CS Inst. Pharmazeutische Chem., Marburg/Lahn, D-35037, Germany
SO Journal of Heterocyclic Chemistry (1996), 33(6), 1791-1796
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
AB N-Boc-protected 2-methylthio-1,3-thiazinium and 2-methylthiothiazolium salts obtained from the corresponding 1,3-thiazine-2-thiones and thiazolidine-2-thiones by the action of Me iodide or trimethyloxonium tetrafluoroborate were reacted with vinylogous CH-acidic compds. forming ketene N,S-acetals. The protection group was removed with trifluoroacetic acid whereupon the desired cyclization to pyrido[2,1-b]-1,3-thiazines and thiazolo[3,2-b]pyridines took place.
IT **187829-96-5P 187829-97-6P 187829-99-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 187829-96-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-6-carbonitrile, 7-(4-bromophenyl)-5-imino-2-methyl- (9CI) (CA INDEX NAME)



10634177

RN 187829-97-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-6-carbonitrile, 5-imino-2-methyl-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 187829-99-8 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-6-carbonitrile, 5-[(1,1-dimethylethyl)imino]-2-methyl-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:513348 CAPLUS
DN 125:195354
TI Synthesis and reactions of 2-mercapto-6-thioxothiopyran-3-carboxylate derivatives
AU Rehwald, M.; Schaefer, H.; Gewald, K.; Gruner, M.
CS Institut Organische Chem., Technische Univ. Dresden, Dresden, D-01062, Germany
SO Journal fuer Praktische Chemie/Chemiker-Zeitung (1996), 338(6), 516-522
CODEN: JPCCEM; ISSN: 0941-1216
PB Barth
DT Journal
LA German
GI



I



II

AB 6-Aminothiopyran-2-thiones react with H2S in the presence of pyridine and Et3N to yield 6-thioxothiopyran-2-thiolates. Methylation of the latter gives the methylthio compds. I and II [X = S with R = Me, R1 = Et, R2 = CN; RR1 = (CH2)4, R2 = CN; R = H, R1 = Ph, R2 = CO2Et]. Further methylation of I or II (X = S, R = Me, R1 = Et, R2 = CN) yields the corresponding thiapyrylium salt. The reaction of the iminothiopyran I (X = NH, R = Me, R1 = Et, R2 = CN) with CS2 represents another route to the thiopyranthione I (X = S, R = Me, R1 = Et, R2 = CN). The thiopyranthione II (X = S, R = Me, R1 = Et, R2 = CN) undergoes substitution of the MeS group with amines or reacts with PhNHNH2 to the corresponding phenylhydrazone.
IT **180746-40-1P 180746-42-3P 180746-44-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reactions of mercaptothioxothiopyrancarboxylates)
RN 180746-40-1 CAPLUS
CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3-dihydro-2,2-dimethyl-7-phenyl-5-thioxo-, ethyl ester (9CI) (CA INDEX

NAME)



RN 180746-42-3 CAPLUS
CN 1,3,4-Thiadiazolo[3,2-a]pyridin-4-ium, 8-(ethoxycarbonyl)-2,3-dihydro-2,2-dimethyl-5-(methylthio)-7-phenyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 180746-44-5 CAPLUS
CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-8-carboxylic acid, 2-methyl-7-phenyl-5-thioxo-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:231503 CAPLUS
DN 123:143808
TI Regioselectivity in the Westphal Condensation
AU Diaz, Adolfo; Matia, Maria P.; Garcia-Navio, Jose L.; Vaquero, Juan J.; Alvarez-Builla, Julio
CS Departamento de Quimica Organica, Universidad de Alcala, Alcala de Henares, 28871, Spain
SO Journal of Organic Chemistry (1994), 59(26), 8294-6
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
GI

10634177



I

AB The Westphal condensation using unsym. 1,2-diketones has been performed with different α-methylcycloimmonium salts. When 1-aryl-1,2-propanediones were used, the kinetically-controlled regioisomers, e.g. the quinolizinium I, were the major products. However, mixts. of varying composition were obtained when π-excessive aryl groups were present in the 1,2-dicarbonyl fragment.

IT **166886-40-4P 166886-41-5P 166886-44-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselectivity in the Westphal condensation)

RN 166886-40-4 CAPLUS

CN Thiazolo[3,2-a]pyridinium, 2,3,6-trimethyl-7-phenyl-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 166886-41-5 CAPLUS

CN Thiazolo[3,2-a]pyridinium, 2,3,6-trimethyl-7-(4-methylphenyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 166886-44-8 CAPLUS

CN Thiazolo[3,2-a]pyridinium, 2,3,6-trimethyl-7-(4-pyridinyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

L17 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:191728 CAPLUS

DN 118:191728

TI Preparation of condensed thiazole derivatives as drugs for liver diseases

IN Suzuki, Norio; Nakayama, Atsushi; Saijo, Toru; Hasegawa, Masashi;

10634177

Yokohama, Shuichi
PA Daiichi Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 44 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04273883	A2	19920930	JP 1991-34567	19910228
	JP 3353903	B2	20021209		
PRAI	JP 1991-34567		19910228		

OS MARPAT 118:191728
GI


I


II


III

AB The title compds. [I; A = H, C1-10 alkyl, (substituted) C3-7 cycloalkyl, aryl, heteroaryl, O, S, etc.; R1 - R7 = H, substituent; Z = CH2, CH2CH2, O, S, (substituted) imino; dotted line = unsatn. or saturation] are prepared A solution of 2.0 g thione II and 2.1 g ClCH2CHO in HOAc was heated at 50° with stirring to give 0.9 g thiazine derivative III. Also prepared were 119 addnl. I, one of which inhibited D-galactosamine-induced liver disorders with GPT value of 301 ± 48 μ/L at 300 mg/kg orally in rats.

IT **146947-27-5P 146947-33-3P 146947-43-5P**
146947-45-7P 146947-48-0P 146947-49-1P
146947-56-0P 146947-58-2P 146947-59-3P
146947-71-9P 146947-72-0P 146947-74-2P
146947-83-3P 146947-84-4P 146947-92-4P
146948-00-7P 146948-01-8P 146948-16-5P
146948-17-6P 146948-19-8P 146948-20-1P
146948-22-3P 146948-23-4P 146948-33-6P
146948-35-8P 146948-38-1P 146948-40-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as drug for liver disease)

RN 146947-27-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-33-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2,3-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-43-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2,3-diphenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-45-7 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2,8-dicarboxylic acid, 6,7-dihydro-, diethyl ester (9CI) (CA INDEX NAME)



RN 146947-48-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2,8-dicarboxylic acid, 6,7-dihydro-3-methyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 146947-49-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2-carboxylic acid, 8-cyano-6,7-dihydro-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-56-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2,3,8-tricarboxylic acid, 6,7-dihydro-, triethyl ester (9CI) (CA INDEX NAME)



RN 146947-58-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-acetyl-6,7-dihydro-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-59-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-acetyl-6,7-dihydro-3,6,6-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-71-9 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-3-methyl-2-[(octylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-72-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-[(cyclohexylamino)carbonyl]-6,7-dihydro-3-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146947-74-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2-phenyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146947-83-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-3-oxo-2-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146947-84-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-3-oxo-2-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 146947-92-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2,3,6,7-tetrahydro-3-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146948-00-7 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-6,7-dihydro-, diethyl ester (9CI) (CA INDEX NAME)





RN 146948-01-8 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 146948-16-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-2-(phenylmethyl)-3-thioxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146948-17-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-[(2-chlorophenyl)methyl]-2,3,6,7-tetrahydro-3-thioxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146948-19-8 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-3-(methylthio)-2-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146948-20-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-[(2-chlorophenyl)methyl]-6,7-dihydro-3-(methylthio)-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146948-22-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2-phenyl-3-[(phenylmethyl)thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 146948-23-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 6,7-dihydro-2-phenyl-3-[(2-phenylethyl)thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 146948-33-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-3-(2-methoxy-2-oxoethylidene)-2,2-dimethyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)

10634177



RN 146948-35-8 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-3-[2-oxo-2-(2,2,2-trichloroethoxy)ethylidene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146948-38-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 3-(carboxymethylene)-2,3,6,7-tetrahydro-2,2-dimethyl-, 8-(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 146948-40-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-3-[2-(methylamino)-2-oxoethylidene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:101861 CAPLUS
DN 118:101861
TI Reductive and catalytic rearrangements of 2-vinyl-1,3-thiazetidines
AU Capps, Nigel K.; Davies, Gareth M.; Loakes, David; Young, Douglas W.
CS Sch. Chem. Mol. Sci., Univ. Sussex, Falmer/Brighton, BN1 9QJ, UK
SO Tetrahedron (1992), 48(46), 10149-60
CODEN: TETRAB; ISSN: 0040-4020

10634177

DT Journal
LA English
OS CASREACT 118:101861
GI



I



II



III



IV

AB 2-Vinyl-1,3-thiazetidines I (R = R1 = H, Et; R = PhCH2, R1 = Me, Et) undergo a novel rearrangement to give thiazolidines II in good yield on hydrogenation using heterogeneous catalysts. When homogeneous catalysts are used, rearrangement takes a different course and thiazines such as III are formed. Borohydride reduction yields thiolactols such as IV.

IT **145904-13-8P 145904-15-0P 145904-16-1P**
145904-19-4P 145904-24-1P 145904-27-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 145904-13-8 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-5-oxo-, diethyl ester (9CI) (CA INDEX NAME)



RN 145904-15-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2,3-dihydro-2-methyl-2-(methyl-d2)-5-oxo-, diethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145904-16-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2,3-dihydro-2-methyl-2-(methyl-d2)-5-oxo-, diethyl ester, trans- (9CI) (CA INDEX NAME)

10634177

Relative stereochemistry.



RN 145904-19-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2,3-dihydro-2,2-dimethyl-5-oxo-, 3-methyl 8-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 145904-24-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2,3-dihydro-2,2-dimethyl-5-oxo-, 3-ethyl 8-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 145904-27-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-3,8-dicarboxylic acid, 2,3-dihydro-2,2-dimethyl-5-oxo- (9CI) (CA INDEX NAME)



L17 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:515522 CAPLUS
DN 107:115522
TI 2-Methylthiazolium salts as 1,4-dinucleophiles. Thiazolo[3,2-a]pyridinium salts from Westphal condensation
AU Galera, C.; Vaquero, J. J.; Garcia Navio, J. L.; Alvarez-Builla, J.
CS Dep. Quim. Org., Univ. Alcala de Henares, Madrid, Spain

10634177

SO Journal of Heterocyclic Chemistry (1986), 23(6), 1889-92
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 107:115522
GI



I



II

AB Condensation of 2-methylthiazolium salts I (R = H, Me; R1 = Me, Ph; RR1 = CH:CHCH:CH; R2 = Bz, CO2Et) with R3COCOR3 (R3 = e.g. Me, Ph) in the presence of base, yielded thiazolo[3,2-a]pyridinium derivs. II (R4 = H, R2). Results with different substrates are discussed.

IT **110209-18-2P 110209-19-3P 110209-20-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 110209-18-2 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2,3,6,7-tetramethyl-, bromide (9CI) (CA INDEX NAME)



● Br⁻

RN 110209-19-3 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2,3-dimethyl-6,7-diphenyl-, bromide (9CI) (CA INDEX NAME)



● Br⁻

RN 110209-20-6 CAPLUS
CN Thiazolo[3,2-a]pyridinium, 2,3-dimethyl-6,7-bis(3-nitrophenyl)-, bromide (9CI) (CA INDEX NAME)

10634177





● Br^-

10634177

=> d 1-2 bib abs hitstr

L19 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:319723 CAPLUS
DN 138:338175
TI Preparation of alkyne matrix metalloproteinase inhibitors for treatment of cancer and arthritis
IN Bunker, Amy Mae; Harter, William Glen; Hicks, James Lester; O'Brien, Patrick Michael; Pham, Ly Thi; Picard, Joseph Armand; Roark, William Howard
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032999	A1	20030424	WO 2002-IB3057	20020802
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003144274	A1	20030731	US 2002-264764	20021004
PRAI	US 2001-329216P	P	20011012		
	WO 2002-IB3057	W	20020802		

OS MARPAT 138:338175
GI



$G^1-C\equiv C-B-G^2$ I

II

AB Title compds. I [wherein G1 and G2 = independently (un)substituted (CH2)m-(hetero)aryl; m = 0-6; B = (un)substituted Ph, pyrimidinyl, pyridyl, quinolinyl, 2,3-benzothiazinyl, benzo[1,2,4]thiadiazinyl, thiazolo[3,2-a]pyridinyl, thieno[3,2-c]pyridinyl, etc.; or pharmaceutically acceptable salts or tautomers thereof] were prepared as selective inhibitors of matrix metalloproteinase 13 (MMP-13). For example, formylation of 4-bromoaniline gave N-(4-bromophenyl)formamide (99.2%), which was reduced to the methylamine (95%) using BH3•SMe2 in THF. Reaction of (4-bromophenyl)methylamine with ClSO2NCO and MeNO2, followed addition of AlCl3 provided 7-bromo-4-methyl-1,1-dioxo-1,4-dihydro-2H-benzo[1,2,4]thiadiazin-3-one (77.4%). N-benzylation (93.5%) and substitution with PhCH2C.tplbond.CH using CuI, Pd(PhCN)2Cl2, P(Bu-t)3, and NH(Pr-i)2 gave II. The latter selectively inhibited the catalytic activity of MMP-13 (CD) over MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, and MMP-13 (CD) with IC50 values of 2.2 μM, >100 μM, >30 μM, >30 μM, >30 μM, >100 μM, and >100 μM, resp. Thus, I are useful for treating diseases mediated by MMP-13, including cancer and arthritis (no data). Specific formulations of I are also disclosed.

IT **515172-54-0P**, 2-[3-(Phenyl)prop-1-ynyl]-6-benzyl-4H-thiazolo[3,2-a]pyridin-5-one **515172-55-1P**, 2-[3-(4-Methoxyphenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-56-2P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-methoxyphenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-57-3P**, 2-[3-(3-Methoxyphenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-58-4P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-methoxyphenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-59-5P**, 2-[3-(4-Cyanophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-60-8P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-cyanophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-61-9P**, 2-[3-(3-

Cyanophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-62-0P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-cyanophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-63-1P**, 2-[3-(4-Fluorophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-64-2P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-fluorophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-65-3P**, 2-[3-(3-Fluorophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-66-4P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-fluorophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-67-5P**, 2-[3-(4-Chlorophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-68-6P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-chlorophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-69-7P**, 2-[3-(3-Chlorophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-70-0P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-chlorophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-71-1P**, 2-[3-(4-Bromophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-72-2P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-bromophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-73-3P**, 2-[3-(3-Bromophenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-74-4P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-bromophenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-75-5P**, 2-[3-(4-Methanesulfanylphenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-76-6P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-methanesulfanylphenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-78-8P**, 2-[3-(3-Methanesulfanylphenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-80-2P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-methanesulfanylphenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-82-4P**, 2-[3-(4-Methylphenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-83-5P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(4-methylphenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-85-7P**, 2-[3-(3-Methylphenyl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-87-9P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(3-methylphenyl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515172-89-1P**, 2-[3-(Pyridin-4-yl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515172-91-5P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(2-methoxypyridin-4-yl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515174-25-1P**, 2-[3-(2-Methoxypyridin-4-yl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515174-26-2P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(pyridin-3-yl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one **515174-27-3P**, 2-[3-(Pyridin-3-yl)prop-1-ynyl]-6-(4-carboxybenzyl)-4H-thiazolo[3,2-a]pyridin-5-one **515174-28-4P**, 6-(4-Methanesulfonylbenzyl)-2-[3-(pyridin-4-yl)prop-1-ynyl]-4H-thiazolo[3,2-a]pyridin-5-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP-13 inhibitor; preparation of alkyne MMP-13 inhibitors for treatment of cancer and arthritis)

RN 515172-54-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 6-(phenylmethyl)-2-(3-phenyl-1-propynyl)-(9CI) (CA INDEX NAME)



RN 515172-55-1 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-methoxyphenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-56-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(4-methoxyphenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-57-3 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-58-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(3-methoxyphenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-59-5 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-cyanophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-60-8 CAPLUS
CN Benzonitrile, 4-[3-[6-[[4-(methylsulfonyl)phenyl]methyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-2-yl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 515172-61-9 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-cyanophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-62-0 CAPLUS
CN Benzonitrile, 3-[3-[6-[[4-(methylsulfonyl)phenyl]methyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-2-yl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 515172-63-1 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-fluorophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-64-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(4-fluorophenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-65-3 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-fluorophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-66-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(3-fluorophenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-67-5 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-chlorophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-68-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(4-chlorophenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-69-7 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-chlorophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-70-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(3-chlorophenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-71-1 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-bromophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-72-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(4-bromophenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-73-3 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-bromophenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-74-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(3-bromophenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-75-5 CAPLUS
CN Benzoic acid, 4-[[2-[3-[4-(methylthio)phenyl]-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-76-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 6-[[4-(methylsulfonyl)phenyl]methyl]-2-[3-[4-(methylthio)phenyl]-1-propynyl]- (9CI) (CA INDEX NAME)



RN 515172-78-8 CAPLUS
CN Benzoic acid, 4-[[2-[3-[3-(methylthio)phenyl]-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-80-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 6-[[4-(methylsulfonyl)phenyl]methyl]-2-[3-[3-(methylthio)phenyl]-1-propynyl]- (9CI) (CA INDEX NAME)



RN 515172-82-4 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-methylphenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-83-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(4-methylphenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-85-7 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-methylphenyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-87-9 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(3-methylphenyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-89-1 CAPLUS
CN Benzoic acid, 4-[[5-oxo-2-[3-(4-pyridinyl)-1-propynyl]-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515172-91-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 2-[3-(2-methoxy-4-pyridinyl)-1-propynyl]-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 515174-25-1 CAPLUS
CN Benzoic acid, 4-[[2-[3-(2-methoxy-4-pyridinyl)-1-propynyl]-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)

10634177



RN 515174-26-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 6-[[4-(methylsulfonyl)phenyl]methyl]-2-[3-(3-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RN 515174-27-3 CAPLUS
CN Benzoic acid, 4-[[5-oxo-2-[3-(3-pyridinyl)-1-propynyl]-5H-thiazolo[3,2-a]pyridin-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 515174-28-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridin-5-one, 6-[[4-(methylsulfonyl)phenyl]methyl]-2-[3-(4-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:213095 CAPLUS
DN 118:213095
TI Preparation of pyrrolo[2,1-b]thiazole, thiazolo[3,2-a]pyridine, and thiazolo[2,3-c][1,4]thiazine derivatives for prevention and treatment of liver diseases
IN Suzuki, Norio; Nakayama, Atsushi; Hasegawa, Masashi; Yokohama, Shuichi; Saijo, Toru
PA Daiichi Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04261186	A2	19920917	JP 1991-20969	19910214
	JP 3410479	B2	20030526		
PRAI	JP 1991-20969		19910214		

OS MARPAT 118:213095
GI



I

AB The title compds. [I; R1, R2-R6 = H, substituent; when the bond between 5- and 6-position is double bond, one of R3 and R4 and one of R5 and R6 are absent; or one of R3 and R4 is bonded to one of R5 and R6 to form C3-5 alkylene optionally having ≥1 substituent(s); or CR3R4 = CO, CS; Z = single bond, CH2, CH2CH2, O, S, SO, SO2, NR9; R9 = C1-10 alkylene] are prepared Thus, 4.85 g DBU was added to a stirred solution of 4.97 g iso-Pr 2-thioxopyrrolidine-3-carboxylate and 2.80 g 2-chloroacrylonitrile (II) in CH2Cl2, after 15 min. addnl. 0.56 II and 0.95 g DBU were added, and the mixture was stirred for 10 min to give 2.67 g iso-Pr 2-cyano-2,3,5,6-tetrahydropyrrolo[2,1-b]thiazole-7-carboxylate. Iso-Pr 2-(N-methylcarbamoyl)-2,3,5,6-tetrahydropyrrolo[2,1-b]thiazole-7-carboxylate at 200 mg/kg p.o. in D-galactosamine-treated rats reduced the serum GPT level from 1921±423 U/L to 589±168 U/L, vs. 32±2 U/L for normal group. A total of 45 I were prepared

IT **146741-32-4P 146741-33-5P 146741-34-6P**
146741-39-1P 146741-41-5P 146741-53-9P
146741-54-0P 146741-62-0P 146741-63-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of liver disease)

RN 146741-32-4 CAPLUS

CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-cyano-2,3,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 146741-33-5 CAPLUS

CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-cyano-2,3,6,7-tetrahydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146741-34-6 CAPLUS

CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-cyano-2,3,6,7-tetrahydro-6,6-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 146741-39-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2,8-dicarboxylic acid, 2,3,6,7-tetrahydro-, 2-ethyl 8-(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 146741-41-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2-(aminocarbonyl)-2,3,6,7-tetrahydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 146741-53-9 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2,8-dicarboxylic acid, 2,3,6,7-tetrahydro-, diethyl ester (9CI) (CA INDEX NAME)



RN 146741-54-0 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-2,8-dicarboxylic acid, 2,3,6,7-tetrahydro-6,6-dimethyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 146741-62-0 CAPLUS

10634177

CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-2-[(methylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 146741-63-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyridine-8-carboxylic acid, 2,3,6,7-tetrahydro-2-[(methylamino)carbonyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



=> s l12 not l18
L20 4 L12 NOT L18

=> d 1-4 bib abs hitstr

L20 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:342561 CAPLUS
DN 139:214379
TI Oxidative cyclization of N-methyl- and N-benzoylpyridylthioureas. Preparation of new thiazolo[4,5-b]- and -[5,4-b]pyridine derivatives
AU Jouve, Karine; Bergman, Jan
CS Unit for Organic Chemistry, Department of Biosciences, Karolinska Institute and Sodertorn University College, Huddinge, SE-14157, Swed.
SO Journal of Heterocyclic Chemistry (2003), 40(2), 261-268
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
OS CASREACT 139:214379
AB Cyclization of N-methyl- and N-benzoylpyridylthioureas, prepared from the corresponding aminopyridines, has been realized using various conditions. With bromine in acetic acid or potassium ferricyanide, the cyclization occurred on the nitrogen of the pyridine ring and pyridinium salts or 1,2,4-thiadiazolo[2,3-a]pyridylidene systems were obtained. On the other hand, treatment of the thioureas with sodium methoxide in N-methylpyrrolidinone (NMP) led to formation of thiazolo[4,5-b]- and -[5,4-b]pyridines, which are interesting targets for biol. evaluation.
IT **588730-04-5P 588730-05-6P 588730-06-7P 588730-07-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of thiazolopyridine derivs. by oxidative cyclization of N-methyl- and N-benzoylpyridylthioureas)
RN 588730-04-5 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 6-bromo-2-(methylamino)-, bromide (9CI) (CA INDEX NAME)

10634177



● Br^-

RN 588730-05-6 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(methylamino)-6-phenyl-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 588730-06-7 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(benzoylamino)-6-bromo-, inner salt (9CI) (CA INDEX NAME)



RN 588730-07-8 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(benzoylamino)-6-phenyl-, inner salt (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:661861 CAPLUS
DN 132:35655
TI Intramolecular oxidative cyclizations in heteroarylthioureas: a versatile pathway to bridgehead heterocyclic systems
AU Castro, Ana; Martinez, Ana
CS Instituto de Quimica Medica (CSIC), Madrid, 28006, Spain
SO Journal of Heterocyclic Chemistry (1999), 36(4), 991-995
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
AB Intramol. oxidns. of N-alkyl-N'-heteroarylthioureas represent a facile and versatile synthetic pathway to fused heterocyclic systems including bridgehead ones. These kinds of heterocycles are the main feature in common biol. active compds.
IT **252270-12-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)

10634177

(intramol. oxidative cyclization in heteroarylthioureas as versatile pathway to bridgehead heterocyclic systems)

RN 252270-12-5 CAPLUS

CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(dimethylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10634177

L20 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:537875 CAPLUS
DN 127:242986
TI Arylimino-1,2,4-thiadiazolidones: a new family of potassium channel openers
AU Martinez, Ana; Castro, Ana; Cardelus, Ignacio; Llenas, Jesus; Palacios, Jose M.
CS Inst. Quim. Med., Madrid, 28006, Spain
SO Bioorganic & Medicinal Chemistry (1997), 5(7), 1275-1283
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier
DT Journal
LA English
AB A series of arylimino-1,2,4-thiadiazolidones were prepared using an efficient synthesis starting from thiadiazolo-pyridinium chlorides. All the compds. showed smooth muscular relaxant properties in rat portal veins. The different behavior under highly depolarized conditions and the reduction of the biol. effect by glyburide suggests that the arylamini-1,2,4-thiadiazolidin-3-ones may act, at least in part, via K+-induced hyperpolarization of vascular smooth cells.
IT **188830-69-5 188830-71-9**, 2-Benzylamino-1,2,4-thiadiazolo[2,3-a]pyridinium chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and characterization of vasorelaxant arylimino-1,2,4-thiadiazolidones)
RN 188830-69-5 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(methylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 188830-71-9 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-[(phenylmethyl)amino]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:169800 CAPLUS
DN 126:264050
TI Base promoted transformation on thiadiazolopyridinium chlorides
AU Martinez, Ana; Castro, Ana; Fayet, J. P.
CS Instituto de Quimica Medica, CSIC, Madrid, 28006, Spain
SO Journal of Heterocyclic Chemistry (1997), 34(1), 337-340
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
AB 1,2,4-Thiadiazolo[2,3-a]pyridinium chlorides undergo a very facile base promoted transformation to give bispyridylimino-1,2,4-thiadiazolidines. The unequivocal structural assignment of these last compds. was achieved by spectroscopic 1H, 13C and 15N two dimensional methods.
IT **188830-69-5 188830-70-8 188830-71-9**

10634177

RL: RCT (Reactant); RACT (Reactant or reagent)
(conversion of thiadiazolopyridinium chlorides to
bis(pyridylimino)thiadiazolidines)

RN 188830-69-5 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(methylamino)-, chloride (9CI)
(CA INDEX NAME)



● Cl⁻

RN 188830-70-8 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-(ethylamino)-, chloride (9CI)
(CA INDEX NAME)



● Cl⁻

RN 188830-71-9 CAPLUS
CN [1,2,4]Thiadiazolo[2,3-a]pyridin-4-ium, 2-[(phenylmethyl)amino]-, chloride
(9CI) (CA INDEX NAME)



● Cl⁻

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT